Phase Ia Study of ChAd63/MVA PvDBP

NCT ID: NCT01816113

Last Updated: 2017-05-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-04-30
• Study Completion Date: 2014-07-31

Brief Summary

This is an open label phase Ia study, to assess the safety of two novel malaria vaccines, ChAd63 PvDBP, with or without MVA PvDBP. Heterologous prime-boost with ChAd63-MVA is, to our knowledge, one of the most potent T cell-inducing subunit vaccine regimens which can importantly also induce antibodies. Previous clinical trials using this regimen expressing ME-TRAP, AMA1 & MSP1, have shown that administering ChAd63 as a prime followed 8 weeks later by MVA as a boost is a very immunogenic schedule (32-34). For this reason, and to provide comparability with previous ChAd63-MVA trials, we propose to use a similar administration schedule.

Conditions

Malaria; Plasmodium Vivax

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Group 1

4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly

Group Type: EXPERIMENTAL

ChAd63 PvDBP 5 x 10^9

Intervention Type: BIOLOGICAL

1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly

Group 2A

4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

Group Type: EXPERIMENTAL

ChAd63 PvDBP 5 x 10^10

Intervention Type: BIOLOGICAL

1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

Group 2B

8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10\^8 pfu 8 weeks later intramuscularly

Group Type: EXPERIMENTAL

ChAd63 PvDBP 5 x 10^10

Intervention Type: BIOLOGICAL

1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

MVA PvDBP 1 x 10^8

Intervention Type: BIOLOGICAL

1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly

Group 2C

8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10\^8 pfu 8 weeks later intramuscularly

Group Type: EXPERIMENTAL

ChAd63 PvDBP 5 x 10^10

Intervention Type: BIOLOGICAL

1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

MVA PvDBP 2 x 10^8

Intervention Type: BIOLOGICAL

1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly

Interventions

ChAd63 PvDBP 5 x 10^9

1 dose of ChAd63 PvDBP 5 x 10\^9 vp intramuscularly

Intervention Type: BIOLOGICAL

ChAd63 PvDBP 5 x 10^10

1 dose of ChAd63 PvDBP 5 x 10\^10 vp intramuscularly

Intervention Type: BIOLOGICAL

MVA PvDBP 1 x 10^8

1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly

Intervention Type: BIOLOGICAL

MVA PvDBP 2 x 10^8

1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy adults aged 18 to 50 years.
• Able and willing (in the Investigator's opinion) to comply with all study requirements.
• Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner.
• For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of vaccination.

Agreement to refrain from blood donation during the course of the study.

-Provide written informed consent.

Exclusion Criteria

• Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.
• Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
• Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon.
• History of clinically significant contact dermatitis.
• Any history of anaphylaxis in reaction to vaccination.
• Pregnancy, lactation or willingness/intention to become pregnant during the study.
• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
• History of serious psychiatric condition.
• Any other serious chronic illness requiring hospital specialist supervision.
• Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
• Suspected or known injecting drug abuse in the 5 years preceding enrolment.
• Seropositive for hepatitis B surface antigen (HBsAg).
• Seropositive for hepatitis C virus (antibodies to HCV) with positive PCR for hepatitis C at screening.
• History of clinical malaria (any species).
• Travel to a malaria endemic region during the study period or within the previous six months.
• Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis.
• Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
• Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adrian V S Hill, MD

Role: PRINCIPAL_INVESTIGATOR

University of Oxford

Locations

Centre for Clinical Vaccinology and Tropical Medicine

Oxford, Oxfordshire, United Kingdom

Countries

United Kingdom

References

Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbe GM, Edwards NJ, Poulton ID, Roberts R, Farid R, Jorgensen T, Alanine DG, de Cassan SC, Higgins MK, Otto TD, McCarthy JS, de Jongh WA, Nicosia A, Moyle S, Hill AV, Berrie E, Chitnis CE, Lawrie AM, Draper SJ. Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. JCI Insight. 2017 Jun 15;2(12):e93683. doi: 10.1172/jci.insight.93683. eCollection 2017 Jun 15.

Reference Type: DERIVED

PMID: 28614791 (View on PubMed)

Other Identifiers

VAC051

Identifier Type: -

Identifier Source: org_study_id